ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2017 American Transplant Congress

April 29-May 3, 2017 in Chicago, IL

View by Title View Sessions
View by Date
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • C-C Chemokine Receptor 5 Polymorphisms and Risk of Antibody-Mediated Rejection in Renal Transplantation.

    J. Lee,1 D. Kim,1 J. Lee,1 S.-K. Kwon,1 S. Song,1 J. Lee,1 B. Kim,2 M. Kim,1 S. Kim,1 Y. Kim,1 K. Huh.1

  • C1q+ and IgG3+ De Novo Donor Specific Antibody Are Associated with Allograft Failure in a Multicenter Cohort.

    C. Schinstock,1 M. Everly,2 M. Samaniego,3 M. Gandhi,1 R. Parikh,4 V. Sharma,4 M. Stegall,1 D. Dadhania.4

  • C3d Assay Result in Potential Transplant Recipients with HLA-DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.

    A. Contreras, A. Casillas, N. Castelan, N. Gonzalez-Tableros, M. Lopez, A. Arvizu, A. De Santiago, J. Alberu, J. Arreola-Guerra.

  • C3d-Binding Anti-DQ DSA Is Associated with a High Risk for Late ABMR and Graft Failure in Stable Kidney Transplant Recipients.

    D. Lee,1 B. Kim,2 J. Kim,3 I. Kim,4 M. Chun.5

  • C4d Immunohistochemistry in Lung Allograft Interstitial Capillaries Lacks Linear Correlation with Donor Specific Antibodies, yet It Is Still Diagnostically Relevant.

    Y. Butt,1 T. Gokaslan,1 V. Kaza,2 F. Torres,2 J. Torrealba.1

  • C5b-9 Deposition in Glomerular Capillaries Is Responsible for Poor Allograft Survival in Antibody-Mediated Rejection.

    V. Goutaudier,1 H. Perrochia,1 M. Marron-Wojewodzki,1 F. Garo,1 C. René,1 N. Pirot,2 G. Mourad,1 M. Le Quintrec.1

  • Calibration of BK Virus Nucleic Acid Amplification Testing to the 1st WHO International Standard for BK Virus.

    S. Tan,1 S. Milligan,2 M. Sahoo,3 N. Taylor,2 B. Pinsky.1,2,3

  • Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?

    A. Prasad,1 A. Yuvaraj,1 D. Briggs,2 N. Krishnan.1

  • Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.

    Y. Natori,1 A. Alghamdi,1 D. Kumar,1 V. Miller,2 P. Ljungman,3 S. Husain,1 A. Humar.1

  • Can We Improve Donation Through Pre-Kidney Transplantation Education Using Internet-Based Resources? An Analysis of Internet Use Patterns Among Hispanics.

    H. Gomez, E. Malagon-Blackwell, J. Caicedo.

  • Can We Successfully Overcome Obesity as a Barrier for Kidney Transplantation?

    K. Zorbas,1 S. Karhadkar,1 S. Rao,2 K. Lau,1 I. Lee,2 A. Gillespie,2 S. Constantinescu,2 A. Karachristos,1 A. Di Carlo.1

  • Candidate Sex and Size Disparity in Liver Offer Acceptance.

    M. Bowring,1 A. Massie,1 C. Haugen,1 J. Ruck,1 D. Segev,1 S. Gentry.1,2

  • Cardiovascular Disease in Japanese Kidney Transplant Recipients.

    M. Okumi, K. Unagami, D. Fujimori, K. Hata, T. Hirai, H. Ishida, K. Tanabe, Japan Academic Consortium of Kidney Transplantation (JACK).

  • Cardiovascular Events Are a Substantial and Increasing Cause of Graft Loss in Liver Transplant Recipients.

    M. Sell, A. Mardis, I. Lee, B. O'Brien, C. Perez, A. Rogers, C. Mardis, N. Patel, J. Fleming, H. Meadows, N. Pilch, K. Chavin, D. Taber.

  • Carotid Intima-Media Thickness and Myocardial Strain in Pediatric Kidney Transplant Recipients.

    K. Sgambat, S. Clauss, M. Lasota, A. Moudgil.

  • Causes and Long-Term Consequences of Diarrhea After Kidney Transplantation.

    A. Devresse,1 F. Aulagnon,2 A. Scemla,2 L. Morin,2 F. Lanternier,3 D. Anglicheau,2 O. Lortholary,3 C. Legendre,2 V. Avettand-Fenoel,4 J. Zuber.2

  • CCR5-Mediated Recruitment of NK Cells to the Kidney Is Critical for Resistance to Candida albicans Infections.

    J. Lee,1,4 V. Tran,3 H. Kim,1 B. Kwon,1,3 K. Park,1,4 H. Cho.1,2

  • CCR7+CD8+ T Cell Suppresses Effector T Cell Related Allo-Immune Responses in Kidney Transplant Recipients.

    B. Chung, K. Kim, B.-M. Kim, K. Doh, C. Yang.

  • CD16+ Monocytes and Skewed Macrophage Polarization Towards M2 Type Hallmark Heart Transplant Acute Cellular Rejection.

    T. van den Bosch,1 K. Caliskan,2 M. Kraaij,1 A. Constantinescu,2 O. Manintveld,2 P. Leenen,3 J. von der Thüsen,4 M. Clahsen-van Groningen,4 C. Baan,1 A. Rowshani.1

  • CD16a-Activated NK Cells in ABMR Are Highly Similar to CD3-Activated Effector T Cells in TCMR.

    M. Parkes, P. Halloran, L. Hidalgo.

  • CD19+CD38hiCD24hi Immature Transitional B Cells in PBMCs of Tolerant Kidney Recipients of Facilitating Cell-Enriched Hematopoietic Stem Cells and Renal Allografts.

    Y. Wen,1 A. Merchak,1 Y. Huang,1 H. Xu,1 L. Kahn,1 J. Leventhal,2 S. Ildstad.1

  • CD28 Directed Immunotherapy Is More Potent Than Belatacept in a Nonhuman Primate Xenotransplant Model.

    S. Kim,1 L. Higginbotham,1 D. Mathews,1 C. Breeden,1 A. Stephenson,1 C. Larsen,1 M. Ford,1 J. Tector,2 A. Adams.1

  • CD4 and CD8 T Cells: Respectively Reprogrammed and Recapitulated in the Neonate to Induce Transplant Tolerance.

    R. Bascom, K. Tao, L. West.

  • CD4 Depletion Is Necessary and Sufficient for Long-Term Nonhuman Primate Xenotransplant Survival.

    S. Kim, L. Higginbotham, D. Mathews, C. Breeden, A. Stephenson, C. Larsen, M. Ford, J. Tector, A. Adams.

  • CD4 T Cell Depletion Mitigates Ischemic Hepatocellular Damage and Promotes Immune Regulation in Mouse Liver Allografts.

    S. Kageyama, K. Nakamura, R. Busuttil, J. Kupiec-Weglinski, Y. Zhai.

  • CD4 T Cell Migration Across Lymphatic Endothelium Is Enhanced by Sphingosine 1-Phosphate (S1P) and Differentially Regulated by S1P Receptors (S1PR).

    Y. Xiong,1 C. Brinkman,1 K. Hippen,2 B. Blazar,2 J. Bromberg.1

  • CD4 T Cells and Co-Engagement with Foreign Protein Are Required in Antibody Response to Non-Self Blood Group A-Antigen.

    I. Adam, B. Motyka, L. West.

  • CD4+/CD8+ T Cell Ratio as a Predictive Marker for Early Graft Failure in Pig to Non-Human Primate Islet Xenotransplantation with Immunosuppression.

    S. Choi,1,3,4 H.-J. Kim,1,2,3,4 I.-H. Yoon,1,2 J.-S. Kim,1,2,6 S.-J. Kang,1,2,3,4 H.-Y. Nam,1,2 B.-H. Min,1 J.-S. Shin,1,6 J.-M. Kim,1,6 Y.-H. Kim,1,5 W.-W. Lee,1,2,3,4 C.-G. Park.1,2,3,4,6

  • CD4+CD28null T Cells Require IL-15 & IL-21 to Become Alloresponsive.

    B. Dedeoglu, N. Litjens, R. Kraaijeveld, W. Verschoor, C. Baan, M. Betjes.

  • CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells Facilitate Prolongation of Graft Survival in Old Recipient Mice Treated with Rapamycin.

    T. Heinbokel, M. Quante, K. Minami, A. Elkhal, S. Tullius.

  • CD40/CD40 Ligand Signal Controls Cytotoxic Ability of Natural Killer Cells After Invariant Natural Killer T Cell Stimulation.

    H. Fukuda,1 T. Hiai,1 R. Ishii,1 H. Katsumata,1 T. Kanzawa,1 S. Miyairi,1 M. Ikemiyagi,1 Y. Ishii,2 M. Okumi,1 K. Tanabe.1

  • CD47 Blockade Reduces Ischemia/Reperfusion Injury in Donation After Cardiac Death Rat Kidney Transplantation.

    X. Wang,1 M. Xu,1 J. Jia,1 Z. Zhang,1 J. Gaut,2 G. Upadhya,1 P. Manning,3 Y. Lin,1 W. Chapman.1

  • CD8+ TAb-supp Cells Are Key Inhibitors of Humoral Alloimmunity by Inhibiting CD4+TFH Cells and Killing Germinal Center B Cells.

    J. Zimmerer, C. Avila, S. Elzein, B. Ringwald, R. Warren, G. Bumgardner.

  • CD8+ TAb-supp Cells Suppress the Production of Multiple Alloantibody Isotypes in Response to MHC-Mismatched Cellular and Vascularized Allografts.

    J. Zimmerer, C. Avila, S. Elzein, B. Ringwald, G. Bumgardner.

  • Cell-Subset Diversity in Adipose Derived Regenerative Cells Used in Renal Ischemic Reperfusion Injury Treatment.

    R. Lathan,1 R. Ghita,1,2 D. Hillyard,1 P. Mark,1,2 M. Clancy.1,2

  • Center Volume Does Not Influence the Risk Associated with Using High DRI Donor Livers.

    S. Black,1 E. Beal,1 K. Mumtaz,2 D. Hayes Jr.,3 A. El-Hinnawi,1 K. Washburn,1 D. Tumin.4

  • Center-Level Differences in Outcomes Following High-KDPI Kidney Transplants.

    L. Wu, A. Massie, X. Luo, M. Bowring, D. Segev.

  • Chagas Disease and Outcome in Kidney Transplant.

    M. Taylor, A. Martinoia, S. Di PIetrantonio, M. Torres, H. Petrone.

  • Challenges for the Travelling Donor: Variability Between Donor Work-Up and Donor Surgery in the Canadian Kidney Paired Donation Program.

    B. Reikie, T. Kroczak, T. McGregor.

  • Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.

    K. Soliman, A. Posadas Salas, D. Taber.

  • Change in QTC Interval After Kidney Transplant.

    E. Lai, V. Acharya, D. Nguyen, E. Graviss, W. Suki.

  • Changes in Peripheral Blood Gene Expression Profile After Calcineurin Inhibitor (CNI) Withdrawal in Kidney Transplant Recipients.

    P. Cravedi,1 W. Zhang,1 D. Salomon,2 M. Fribourg,1 G. Remuzzi,3 E. Gotti,3 F. Casiraghi,3 Z. Yi,1 P. Heeger,1 CTOT09, ATHENA Consortia.

  • Changes in Urinary Neutrophil Gelatinase Associated Lipocalin Combined with Urine Cytokines and Microalbuminuria as Predictors for Interstitial Fibrosis and Tubular Atrophy in Kidney Transplantation: A Matched-Pair Tissue Cohort Study.

    W. Chancharoenthana,1 A. Leelahavanichkul,1 S. Wattanatorn,1 J. Issara-Amphorn,2 Y. Avihingsanon,1 K. Praditpornsilpa,1 N. Townamchai.1

  • Characteristics and Performance of Unilateral Deceased Donor Kidney Transplants.

    S. Husain,1 S. Lee,1 S. Mohan,1 S. Pastan,2 R. Patzer,2 M. Chiles.1

  • Characterization of a B Lymphocyte Signature Predictive of Chronic Lung Allograft Dysfunction.

    C. Brosseau,1,2 M. Durand,1,2 E. Durand,1,2 J. Loy,2 A. Foureau,2 P. Lacoste,2 P.-J. Royer,2 A. Magnan,2 S. Brouard.1

  • Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.

    R. Rajalingam,1 D. Kopchaliiska,1 O. Buenaventura,1 M. Singh,2 S. Tomlanovich.2

  • Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.

    J. Driscoll,1 S. Tremblay,1 P. Brailey,1 A. Girnita,1 R. Alloway,1 B. Aronow,2 H. Singh,2 E. Woodle.2

  • Charlson Comorbidity Index (CCI) as Prognostic Indicator of Outcomes in Older Patients Undergoing Renal Transplantation.

    A. Asderakis, U. Contractor, U. Khalid, P. Donato, L. Szabo.

  • Chimerism-Related Allotolerance Is Induced by Exosome Acquisition and Reprogramming of Host Dendritic Cells.

    D. Lema,1 W. Bracamonte-Baran,2 E. Jankowska-Gan,1 F. Claas,3 J. van Rood,3 A. Mulder,3 W. Burlingham.1

  • Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience.

    S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

  • Chronic Hepatitis E-Genotype 3 Infection in Transplant Recipients: A Single Kidney and Pancreas Transplant Centre Experience.

    A. Kousios,1 R. Charif,1 E. Sanchez,2 S. Khan,3 F. Regan,4 S. Ijaz,5 D. Muir,2 B. Smith,3 R. Tedder,5 D. Taube,1 J. Galliford.1

  • Cibinetide (ARA 290), the Innate Repair Receptor Ligand, Improves Engraftment in Pancreatic Islet Transplantation by Protecting Islets and Reducing Inflammatory Reactions.

    M. Watanabe,1 M. Han Yao,1 H. Zemack,1 B.-G. Ericzon,1 A. Cerami,2 M. Brines,2 T. Lundgren,1 M. Kumagai-Braesch.1

  • Ciprofloxacin for Urinary Tract Infection Prophylaxis in Post-Renal Transplant Patients with Ureteral Stent Placement.

    P. Kakadiya, M. Levy, G. Gupta, A. King, S. LeCorchick.

  • Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts.

    C. Gosset, D. Viglietti, M. Rabant, E. Pillebout, A. Bouquegneau, J. Taupin, D. Glotz, C. Legendre, J. Duong Van-Huyen, A. Loupy, C. Lefaucheur.

  • Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.

    S. Luque,2 M. Lúcia,4 M. Jarque,2 E. Crespo,2 E. Melilli,1 J. Martorell,3 J. Cruzado,1,2 J. Torras,1,2 J. Grinyó,1,2 O. Bestard.1,2

  • Circulating Exosomes Isolated from Human Lung Transplant Recipients with Rejection Are Immunogenic and Induce Antibodies to Lung Associated Self-Antigens, Kα1 Tubulin and Collagen-V.

    M. Gunasekaran, M. Sharma, S. Bansal, S. Biswas Roy, R. Walia, R. Bremner, M. Smith, T. Mohanakumar.

  • Circulating Inflammatory Factors in Deceased Organ Donors Result in Innate Immune Activation.

    T. Brennan, L. Lin, J. Pollara.

  • Classification of Fibromuscular Dysplasia in Kidney Donors Based on Severity and Extent of Lesion.

    M. Gonzalez Suarez, H. Amer, I. Jaffer, T. Vrtiska, A. Rule, M. Prieto, S. Textor.

  • Clearance of Transaminases During Normothermic Ex Vivo Liver Perfusion.

    M. Bral,1 N. Aboelnazar,2 B. Gala-Lopez,2 S. Hatami,2 D. Freed,1 A. Shapiro.1

  • Clinic-Based Medication Education Pilot Program.

    N. Sulejmani,1 H. Albanna,1 T. Rendulic,2 B. Summers,1 A. Jantz.1

  • Clinical and Histopathologic Features of Antibody Mediated Rejection (ABMR) in Highly Sensitized (HS) vs Non-Sensitized (NS) Pediatric Renal Transplant Recipients.

    J. Steggerda, I. Kim, M. Haas, X. Zhang, A. Wang, H. Pizzo, E. Kamil, S. Jordan, D. Puliyanda.

  • Clinical and Molecular Significance of Microvascular Inflammation Negative Transplant Glomerulopathy.

    M. Lubetzky,1 N. Hayde,1 P. O Broin,2 Y. Bao,1 E. Akalin.1

  • Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients.

    P. Zhang,1 H. Amer,2 C. Schinstock,2 M. Alexander,1 F. Cosio,2 M. Stegall,3 L. Cornell.1

  • Clinical Correlation of Endomyocardial Biopsies Molecular Profiling: Taking Rejection Diagnosis Beyond Histology.

    L. Potena,1 L. Borgese,1 A. Gaudenzi,1 V. Agostini,1 J. Reeve,2 M. Masetti,1 F. Grigioni,1 O. Leone,1 P. Halloran.

  • Clinical Evaluation of the Safety and Preliminary Efficacy of Continuous Infusion of Treprostinil to Prevent Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients.

    O. Almazroo,1 M. Miah,1 V. Pillai,1 A. Humar,2 A. Tevar,2 C. Hughes,2 A. AlKhafaji,3 A. Demetris,4 S. Dermont,2 S. Fedorek,2 H. Johnson,1 R. Lopez,2 R. Planinsic,2 B. Sengupta,2 I. Sethu,2 M. Sturdevant,2 S. Ziobert,1 R. Venkataramanan.1,2,4

  • Clinical Experience with Novel Cephalosporin/Beta-Lactamase Inhibitor Combinations in the Treatment of Multidrug Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Recipients.

    P. Nambiar,1 K. Brizendine,1 V. Athans,2 E. Cober.1

  • Clinical Impact of Strength and Class of Pre transplant Donor Specific Antibody on Kidney Transplant Recipient Receiving Steroid Free Maintenance Immunosupression Regimen.

    O. Adebiyi, O. Simo, S. Hussain, D. Mishler, W. Goggins, T. Taber, A. Sharfuddin, M. Yaqub.

  • Clinical Outcome of Pancreas Transplantation in Elderly Patients with Diabetes Mellitus.

    J. Jung,1 J. Choi,2 S. Shin,2 Y. Kim,2 D. Han.2

  • Clinical Outcomes in Older Kidney Transplant Recipients. A Single Center Experience.

    L. Kamal, N. Hayde, P. Bedi, M. Lubetzky, M. Ajaimy, G. DeBoccardo, E. Akalin.

  • Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.

    E. Ko,1,2 J. Yu,1,2 C. Yang,1,2 B. Chung,1,2 Korean Organ Transplantation Registry (KOTRY).

  • Clinical Outcomes of Kidney Transplant Recipients by Steroid Early Withdraw Protocol with Basiliximab Induction.

    Y. Takada, K. Hotta, D. Iwami, H. Higuchi, T. Hirose, H. Sasaki, N. Shinohara.

  • Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Stable Kidney Recipients.

    C.-K. Oh,1 S.-J. Kim,2 K. Huh,3 S. Kim,4 J. Jeon,5 S. Han,6 H. Cho,7 Y. Kwon,8 S. Lee,1 Y. Kim.3

  • Clinical Risk Factors for Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTRs): Results of an International Cohort Study.

    N. Law,1 B. Hamandi,1 C. Fegbeutel,2 F. Silveira,3 E. Verschuuren,4 P. Ussetti,5 P. Chin-Hong,6 A. Solé,7 C.-L. Holmes-Liew,8 E. Billaud,9 P. Grossi,10 O. Manuel,11 D. Levine,12 R. Barbers,13 D. Hadjiliadis,14 L. Singer,1 S. Husain.1

  • Clinical Significance of Alloantibodies in Hand Transplantation: Impact on Rejection and Functional Outcome.

    E. Berglund,1 M. Andersen Ljungdahl,1 D. Bogdanovic,1 D. Berglund,3 J. Wadström,1 A. Weissenbacher,2 P. Petruzzo,4 S. Schneeberger.2

  • Clinical Utility of Viral miRNA in Urinary Exosomes to Diagnose BK Virus Nephropathy After Kidney Transplantation.

    J.-W. Seo,1 Y. Lee,1 H. Moon,1 Y. Kim,1 K.-H. Jeong,1 J.-Y. Moon,1 C.-D. Kim,2 J. Park,3 B. Chung,4 Y.-H. Kim,5 S.-H. Lee.1

  • Clinically Relevant Immunosuppression Promotes MCMV Reactivation and Dissemination Following Transplantation of Latently Infected Kidneys.

    Z. Zhang,1 S. Yan,1 L. Zhao,1 S. Kurian,2 M. Hummel,1 D. Salomon,2 M. Abecassis.1

  • Clusterin Levels at 3-Months Associate with DGF and 12-Month Fibrosis – Reinforcing the Early Injury to Fibrosis Continuum.

    M. Menon,1 L. Liriano-Ward,2 N. Philippe,1 C. Wei,1 W. Zhang,1 Z. Yi,1 K. Keung,2 P. O'Connell,2 B. Murphy.1

  • CMV and BK Virus Infections in Kidney Transplant Recipients Receiving an mTORi-Based Regimen versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis.

    B. Tanios,1 S. Mallat,1 H. Itani,1 T. Lotfi,1 S. Gabardi,2 E. Akl,1 J. Azzi.2

  • CMV Infection in Renal Transplant Recipients: Incidence and Efficacy of Prophylaxis According to Cytokine Single Nucleotide Polymorphisms.

    I. Perez-Flores, M. Moreno De La Higuera, N. Calvo Romero, B. Rodriguez Cubillo, A. Shabaka, M. Calvo Arevalo, V. Lopez De La Manzanara, A. Sanchez-Fructuoso.

  • CMV-Infected Kidney Grafts Drive the Expansion of Blood-Born CMV-Specific T-Cells Restricted by Shared HLA Molecules Through Presentation on Donor's Cells.

    P. Gatault,1,2 S. Al-Hajj,1 J. Noble,1,2 E. Chevallier,1,2 M. Piollet,1 C. Forconi,1 R. Lemoine,1 J.-M. Halimi,1,2 M. Büchler,1,2 C. Baron.1,2

  • CMV-Specific CD4+ T Cells in CMV-IgG-Seronegative Individuals Protect from CMV Viremia Following Transplantation with a CMV-Seropositive Donor Kidney.

    N. Litjens, L. Huang, B. Dedeoglu, R. Meijers, M. Betjes.

  • Co-Stimulation Blockade to Minimize and Withdraw Long Term Calcineurin Inhibitors (CNI) in Simultaneous Pancreas and Kidney Transplant (SPK).

    P. Stock,1 R. Mannon,2 B. Armstrong,3 D. Ikle,3 M. Robian,4 Y. Morrison,4 J. Odorico,5 J. Fridell,6 A. Mehta,7 K. Newell.7

  • Coagulation Pathway Perturbations Associated with Pig-to-Baboon Lung Xenotransplantation.

    S. Sendil, B. French, O. Siddiqui, D. Parsell, C. Laird, A. Cimeno, S. Dahi, L. Burdorf, A. Azimzadeh, R. Pierson III.

  • Combination αCD28+αCD40 Costimulation Blockade Attenuates Acute and Chronic Rejection in Non-Human Primates.

    N. O'Neill, T. Zhang, W. Sun, G. Braileanu, X. Cheng, I. Tatarov, W. Hassanein, A. Azimzadeh, R. Pierson.

  • Combination Therapy of iNKT Cell Ligand and CD40-CD154 Signal Blockade Establishes Islet Allograft Tolerance in Non-Myeloablative Bone Marrow Transplant Recipients.

    T. Kanzawa,1 T. Hirai,1 R. Ishii,1 M. Okumi,1 H. Ishida,1 Y. Ishii,2 K. Tanabe.1

  • Combined Dual-Kidney Liver Transplantation in the United States: A Review of UNOS/OPTN Data Between 2002 and 2012.

    G. Shekhtman, E. Huang, E. Lum, G. Danovitch, P.-T. Pham, B. Abdalla, S. Bunnapradist.

  • Combined Endoscopic and Percutaneous Cholangiography for Biliary Anastomotic Stricture in Adult Right-Lobe Living-Donor Liver Transplantation.

    A. Thorat,1 W.-H. Huang,2 C.-J. Yu,2 C.-Y. Peng,2 H.-R. Yang,1 C.-C. Yeh,1 T.-H. Chen,1 S.-C. Hsu,1 L.-B. Jeng.1

  • Combined Perfusion of Liver and Kidney Enhances the Protective Effects of Normothermic Perfusion on Donation After Cardiac Death Porcine Livers.

    Z. Guo, F. Ji, X. He, G. Chen.

  • Combining Neural Stem Cell Transplantation with Mixed Hematopoietic Chimerism Promotes Restoration of Self-Tolerance in Established Experimental Autoimmune Encephalomyelitis.

    W. Orent, J. Marino, B. Gonzalez Nolasco, J. Paster, A. Harney, D. Sachs, G. Benichou.

  • Commonly Expressed Living Donation Fears and Concerns by Non-Directed (Altruistic) Living Kidney Donors in the United States.

    A. Maghen,1 G. Vargas,1 S. Connor,1 S. Nassiri,1 E. Hicks,2 L. Kwan,1 S. Maliski,3 J. Veale.1

  • Community Health, Center Proximity, and Liver Transplant Waitlist Mortality.

    R. Lynch,1 K. Ross,1 D. Goldberg,2 R. Patzer.1

  • Comparative Analysis of Four Surgical Techniques in More Than 700 Pancreas Transplantes in a Single Center.

    M. Perosa, J. Branez, L. Mota, B. Zeballos, H. Noujaim, L. Ianhez, D. Machado, L. Alvim, M. Paredes, T. Genzini.

  • Comparing Outcomes Between Technical Variant Liver Allografts and Whole Allografts in Pediatric Liver Transplantation: A Single Center's Experience.

    A. Gallo,1 J. Lee,1 M. Damian,2 D. Stoltz,1 C. Bonham,1 C. Esquivel,1 J. Mendoza.3

  • Comparing Outcomes of ABO Incompatible to DSA Positive/CDC-AHG Negative Kidney Transplantation.

    T. Kitrungphaiboon,1 N. Townamchai,1 D. Saengpanit,1 K. Iampenkhae,2 K. Jutivorakool,1 Y. Avihingsanon,1 K. Praditpornsilpa.1

  • Comparing Renal Function Recovery and Long Term Outcomes in Recipients of Standard and Expanded Criteria Donor Kidney Transplants.

    S. Sandal, M. Cantarovich, S. Paraskevas, N. Almaghrawi, P. Chaudhury, J. Tchervenkov.

  • Comparing the Role of Post-Transplant Readmissions and Bed Days on Total One Year Cost of Care.

    W. Bannister,1 M. Schnitzler,2 J. Tao,1 A. Bonagura,1 B. Laihinen,1 F. Irwin,1 C. Horstman.1

  • Comparison Between IgG, C1q and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.

    M. Moreno Gonzales,1 D. Mitema,2 B. Smith,3 C. Schinstock,3 M. Stegall,3 M. Gandhi.3

  • Comparison of Local Recurrence Rates Between Endhole vs Anti-Reflux Catheters in Patients Undergoing DEB-TACE for Solitary LR-5 HCC Tumors.

    A. Arepally, L. Stein, R. Shrestha, M. Tully, S. Citron, A. Cherian, H. Pollinger, M. Bosley, R. Raymond.

  • Comparison of Locoregional Therapies for Hepatocellular Carcinoma in Liver Transplant Recipients.

    M. Chen, B. Philosophe.

  • Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).

    H. Tedesco,1 W. Irish,2 K. Dharmesh,3 D. Patel,3 D. Cibrik.4

  • Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant.

    D. Cibrik,1 W. Irish,2 K. McCague,3 D. Patel,3 H. Tedesco.4

  • Comparison of Long-Term Survival Outcome Between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria – A Single-Center Experience.

    K. Ng,1 K. Chok,1 A. Chan,1 T. Wong,1 J. Fung,2 C.-M. Lo.1

  • Comparison of the Estimated and Measured Glomerular Filtration Rate in Kidney Donor Candidates.

    C. Akhimiona, W. Suki, D. Nguyen, E. Graviss.

  • Compartmental Infiltration of Kidney Allograft with Monocyte-Macrophage Subtypes Defines the Type of Rejection.

    T. van den Bosch,1 M. Clahsen-van Groningen,2 F. Rezaee,3 D. Hesselink,1 D. Nieboer,4 E. Steyerberg,4 C. Baan,1 A. Rowshani.1

  • Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.

    C. Lefaucheur,1 B. Sis,2 D. Viglietti,1 L. Hidalgo,2 O. Aubert,1 D. Glotz,1 C. Legendre,1 A. Zeevi,3 P. Halloran,2 A. Loupy.1

  • Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients.

    H. Lee,1 E. Han,1 A.-R. Choi,1 K. Park,2 J. Ryu,2 B. Chung,3 C. Yang,3 E.-J. Oh.1

  • Complement Markers in Immunoadsorption Combined with Membrane Filtration.

    P. Malvezzi,1 F. Defendi,2 F. Eskandary,3 T. Jouve,1 L. Rostaing,1 C. Dumestre-Perard,2 G. Böhmig.3

  • Complications Requiring Reoperation After Pediatric Liver Transplantation.

    D. Yoeli, J. Moffett, K. Hosek, R. Ackah, R. Sigireddi, M. Kueht, N. Galvan, R. Cotton, A. Rana, C. O'Mahony, J. Goss.

  • Composite Prognostic Score Improves Clinical Benefit in Kidney Recipients Receiving Standard of Care Therapy for Antibody-Mediated Rejection.

    D. Viglietti, A. Loupy, O. Aubert, E. Pillebout, C. Legendre, D. Glotz, C. Lefaucheur.

  • Comprehensive Functional Assessment of the Pathogenic Potential of Immunodominant Donor Specific Antibody Following Treatment of Late Antibody Mediated Rejection or Mixed Acute Rejection.

    A. Lichvar,1 E. Portwood,1 P. Brailey,1 S. Tremblay,1 A. Shields,2 B. Abu Jawdeh,1 J. Kremer,2 F. Paterno,1 R. Alloway,1 A. Girnita,1 E. Woodle.1

  • Concurrent Psychosocial Variables Confound Perioperative and Postoperative Care in Liver Transplant Recipients with Alcoholic Liver Disease.

    S. Sultan,1 M. Hodorowicz,2 J. Powell,1 M. Connelly,1 M. Tuten,2 P. Sacco,2 W. Hutson,1 R. Barth,1 J. LaMattina.1

  • Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.

    J. Cwykiel, N. Filipek, E. Szilagyi, E. Tfaily, M. Siemionow.

  • Conservative Management of Pneumatosis Intestinalis After Pediatric Liver Transplantation.

    R. Hendrickson, J. Ryan, L. Dandridge, W. Andrews, J. Daniel, R. Fischer, D. Rivard.

  • Contemporary Outcomes and Risk Factors of Acute Graft-versus-Host Disease After Liver Transplant.

    J. Markus, A. Bukannan, B. Kashat, R. Salgia.

  • Continuation of Immunosuppression Appears to Protect Against Allosensitization in Patients Listed for a Second Kidney Transplant.

    S. Kuppachi,1 M. Sanders,1 R. Kalil,1 Z. Stewart,2 C. Thomas.1

  • Contrast-Induced Acute Kidney Injury in Kidney Transplant Recipients: A Meta-Analysis.

    W. Cheungpasitporn,1 C. Thongprayoon,1 M. Mao,1 S. Mao,2 M. D'Costa,1 W. Kittanamongkolchai,1 K. Kashani.1

  • Contributing Factors and Impact of Microbial Contamination in Human Islet Isolation and Transplantation.

    R. Meier, D. Andrey, N. Niclauss, P. Sun, C. van Delden, B. Bedat, S. Demuylder-Mischler, S. Borot, P.-Y. Benhamou, A. Wojtusciszyn, N. Pernin, Y. Muller, D. Bosco, T. Berney.

  • Contribution of γδ T-Cell Subsets and IL-17A Release to Ischemia Reperfusion Injury (IRI) and Kidney Allograft Rejection in Mice.

    A. Thorenz,1 S. Rong,1 N. Völker,1 R. Chen,1 J. Bräsen,2 H. Haller,1 C. Klemann,3 F. Gueler.1

  • Contribution of Donor versus Recipient T Cells in Face Transplant Rejection.

    T. Win,1 N. Murakami,2 I. Avraham-Davidi,1 J. Teague,1 E. Lowry,1 R. Lopdrup,1 E. Bueno,1 A. Chandraker,1 L. Riella,1 B. Pomahac,1 R. Clark.1

  • Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).

    C. Danthu,1 M. Gomes-Mayeras,1 D. Andouard,2 E. Munteanu,1 R. Moulinas,1,4 G. Ligat,2 S. Hantz,1,2 J. Rerolle,3 F. Garnier,1 M. Essig,3 S. Alain.1,2,4

  • Controlled Donation After Circulatory Death (cDCD) Donors May Become Similar to Brain Death Donors (DBD).

    C. Antoine,1 M. Videcoq,2 B. Riou,3 D. Dorez,4 G. Cheisson,5 L. Martin-Lefèvre,6 L. Durand,1 E. Savoye,1 G. Karam,2 B. Barrou.3

  • Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy.

    J. Yoon, S. Kang, S. Kim, C. Baeck, H. Kim, S.-K. Park.

  • Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.

    D. Hesselink,1 N. Shuker,1 J. Osinga,1 M. Clahsen -van Groningen,2 J. Damman,2 C. Baan,1 J. van de Wetering,1 A. Rowshani,1 J. Kal -van Gestel,1 W. Weimar,1 T. van Gelder,3 R. Bouamar.3

  • Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients.

    M. Levine,1 K. Wen.2

  • Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.

    A. Babu,1,2,3 N. Krishnan,2 D. Briggs,3 D. Mitchell,1 S. Daga.1,2,4

  • Correlation of Donor Clinical and Histopathological Characteristics with Graft Function in Kidney Transplant Recipients.

    M. Zachariah,1 C. Yip,1 M. Zachariah, I. Mallawaarachchi,2 A. Dweivedi,2 S. Patel,4 A. Gundroo,1 J. Tomaszewski,1 L. Lin,1 C. Shirley.1

  • Cost Effectiveness of Post-Prophylaxis Screening Strategies for Cytomegalovirus Viremia in CMV D+R- Kidney Transplant Recipients.

    C. Puttarajappa,1 S. Hariharan,1 K. Smith.2

  • Cost-Effectiveness of Renal Machine Perfusion Use After Long Cold Ischemia Time.

    A. Matos,1 D. Malheiro,3 S. Morgado,1 L. Requi[acirc]o-Moura,1 M. Souza-Durão,1,2 E. Tonato,1 M. Nogueira,1 M. Borrelli,1 A. Pacheco-Silva.1,2

  • Costimulation Independent Acute Rejection Requires CD127 Signaling.

    D. Mathews, Y. Dong, S. Kim, C. Breeden, A. Adams.

  • Costimulatory Blockade in Delayed Graft Function.

    J. Von Visger,1 A. Diez,1 U. Nori,1 T. Pesavento,1 R. Pelletier,2 A. Rajab,2 A. El Hinnawi,2 H. Winters.3

  • Course and Outcome of Renal Transplant Recipients Admitted to the Intensive Care Unit (ICU): Long Term Follow-Up.

    A. El-Agroudy,1 A. Alqahtani,1 B. Dandi,2 E. Farid,2 A. Alaradhi.2

  • Course of Donor Specific Anti-HLA Antibodies After Induction Therapy with Rituximab in Renal Transplantation.

    M. Baas,1 W. Allebes,2 M. van den Hoogen,3 I. Joosten,2 L. Hilbrands.1

  • Course of Inflammatory Bowel Disease Activity in Primary Sclerosing Cholangitis Patients Undergoing Liver Transplantation.

    R. Parekh,1 M. Segovia,2 N. Kaur.1

  • Cross-sectional and Serial Evolution of Quality of Life in Elderly Kidney Donors.

    S. Ake,1 D. Berglund,2 S. Jackson,3 A. Matas,2 C. Gross,2 H. Ibrahim.2

  • CTLA4-Ig in Combination with FTY720 Reduces the Frequency of Memory Alloreactive T Cells and Promotes Heart Allograft Survival in Sensitized Recipients.

    S. Khiew,1 J. Yang,1 J. Young,1 J. Chen,1 Q. Wang,1 D. Ying,1 V. Vu,1 M. Miller,2 R. Sciammas,3 M.-L. Alegre,2 A. Chong.1

  • CTLA4-Ig Inhibits Effector CD8+ T Cell Function In Vivo and Rescues Ongoing Acute Allograft Rejection.

    J. Young,1 S. Khiew,1 J. Yang,1 M.-L. Alegre,2 A. Chong.1

  • CTLA4-Ig, Vascularized Bone Marrow and Donor Bone Marrow Cells Successfully Negate the Development of Acute Skin Rejection of Vascularized Composite Allografts in MHC Class I Mismatched Recipients.

    I. Schol, Z. Ng, A. Lellouch, A.-R. Gama, J. Kurtz, C. Cetrulo.

  • CTLA4Ig Suppresses Memory Responses to HLA-A2+ Skin Grafts in a Mouse Model of Allosensitization by Reducing CD138+ Plasma Cells.

    G. Wu, I. Kim, N.-N. Chai, S. Jordan, A. Klein.

  • Cultural Competency of a Mobile, Customized Patient Education Tool for Improving Potential Kidney Transplant Recipients' Knowledge and Decision-Making.

    D. Axelrod,1 C. Kynard-Amerson,2 D. Wojciechowski,3 K. Lentine,4 M. Schnitzler,4 J. Peipert,2 A. Waterman.2

  • Cumulative Deficits Frailty Index for Transplant Candidates Predicts Candidacy for Solid Organ Transplantation.

    R. Varughese,1,2 O. Theou,3 X. Huang,1 O. Famure,1 Y. Li,1 N. Chowdhury,1 E. Renner,1,2 J. Kim,1,2 J. MacIver,1,5 S. Mathur,4 K. Rockwood,3 L. Singer.1,2

  • Current Practice and Center-Level Variation in Simultaneous Liver-Kidney Listing.

    X. Luo, A. Massie, J. Garonzik-Wang, R. Choudhury, A. Shaffer, S. Zhou, D. Segev.

  • Current Practice and Ethical Dimensions of Implementing APOL1 Testing into Living Donor Evaluation: A National Survey.

    E. Gordon,1 C. Wicklund,1 R. Sharp,2 J. Lee,1 C. Johnson,1 J. Friedewald.1

  • Current Status of HIV-to-HIV Transplants in the United States.

    C. Durand,1 A. Tobian,1,3 N. Desai,1 A. Cameron,1 N. Dagher,4 D. Brown,1 S. Halpern,1 S. Bagnasco,1 D. Ostrander,1 A. Redd,1 S. Huprikar,2 B. Haydel,2 S. Lerner,2 S. Florman,2 D. Segev.1

  • Current Treatments for Small Hepatocellular Carcinoma: A Network Meta-Analysis of Randomized Controlled Trials.

    Z. Guo, Z. Zheng, X. He, G. Chen.

  • CXCL12 Modulation of Localized Immune Responses to Subcutaneous Islet Macrocapsulation.

    M. Penson, M. Sremac, R. Sirbulescu, T. Brauns, F. Harrington, M. Poznansky.

  • CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute Kidney Allograft Rejection.

    L. Schiffer,1 F. Wiehler,1 M. Daemmrich,2 K. Hueper,3 M. Mengel,4 A. Thorenz,1 S. von Vietinghoff,1 R. Song,1 M. Schiffer,1 F. Gueler.1

  • Cyclosporine Effects on Blood Pressure Are Exaggerated in Pubertal Girls After Renal Transplantation.

    A. Melk,1 R. Sugianto,1 B. Schmidt,2 K. Krupka,3 B. Höcker,3 B. Tönshoff,3 E. Wühl.3

  • Cytomegalovirus Renal Infection: Rare Manifestation of a Common Post-Transplant Viral Infection — A Case Series.

    M. Posadas Salas, J. Thompson, T. Ngo, S. Self.

  • Cytomegalovirus Viral Load: Characterization of Results from Clinical Specimens.

    S. Kleiboeker.

  • Cytotopic Thrombin Inhibition Prior to Cold Ischaemia Attenuates Microvascular Endothelial Ischaemia-Reperfusion Injury.

    B. Sandhu,1 M. Prendecki,1 J. Crawley,1 N. Galloway-Phillips,1 N. Vallant,1 J. Mason,1 A. Dorling,2 R. Smith,2 C. Pusey,1 V. Papalois.1

Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2023 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences